Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. [electronic resource]
Producer: 20191202Description: 219-225 p. digitalISSN:- 1524-4741
- Aged
- Anthracyclines -- administration & dosage
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Disease-Free Survival
- Female
- Furans -- adverse effects
- Humans
- Ketones -- adverse effects
- Middle Aged
- Neoplastic Cells, Circulating
- Prospective Studies
- Receptor, ErbB-2 -- metabolism
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.